1. Inici
  2. Projectes i Estudis Clínics
  3. Estudio abierto de fase IIIb para evaluar la eficacia y la seguridad de luspatercept (BMS 986346/ACE 536) iniciado a la dosis máxima aprobada en síndromes mielodisplásicos de bajo riesgo (SMD-BR) con una categoría de riesgo muy baja, baja o intermedia según el sistema pronóstico internacional revisado (IPSS R) y que requieren transfusiones de eritrocitos (MAXILUS).

Estudio abierto de fase IIIb para evaluar la eficacia y la seguridad de luspatercept (BMS 986346/ACE 536) iniciado a la dosis máxima aprobada en síndromes mielodisplásicos de bajo riesgo (SMD-BR) con una categoría de riesgo muy baja, baja o intermedia según el sistema pronóstico internacional revisado (IPSS R) y que requieren transfusiones de eritrocitos (MAXILUS).

Dades bàsiques

Protocol:
CA056/1060
EURDRACT:
NCT:
Centre:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Any inici:
2024
Any de finalització:
ENSAYO CLÍNICO

Documents

  • No hi ha documents

Participants

Grups d'Investigació

Finançadors - Promotors

CELGENE CORPORATION

Resultats de l'Assaig Clínic

[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.

Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin

Article. 10.1016/j.farma.2024.08.002. 2024

  • Open Access.

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Castano-Diez, Sandra; (...); Diaz-Beya, Marina

Article. 10.1182/bloodadvances.2024013648. 2025


Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model

Poyatos-Garcia, Javier; (...); Vilchez, Juan J

Article. 10.1186/s13395-024-00353-3. 2024

  • Open Access.

Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain.

Giraldo P; (...); Morales-Conejo M

Article. 10.1016/j.medcli.2024.06.006. 2024

  • Open Access.

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Pastor-Galan, Irene; (...); Hernandez-Boluda, Juan Carlos

Article. 10.1038/s41375-024-02389-2. 2024


Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

  • Open Access.

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

Perez-Lamas, Lucia; (...); Garcia-Gutierrez, Valentin

Article. 10.1007/s00277-024-05906-6. 2024

  • Open Access.

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Goetze, Katharina S. S.; (...); Platzbecker, Uwe

Meeting Abstract. 2024


Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.

Mora E; (...); Sanz J

Article. 10.1038/s41409-024-02298-z. 2024


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.

Crisà E; (...); Santini V

Article. 10.1038/s41375-024-02360-1. 2024

  • Open Access.

Campos d'Estudi

Compartir el projecte